Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.

Mousseau G, Aneja R, Clementz MA, Mediouni S, Lima NS, Haregot A, Kessing CF, Jablonski JA, Thenin-Houssier S, Nagarsheth N, Trautmann L, Valente ST.

MBio. 2019 Jul 2;10(4). pii: e01750-18. doi: 10.1128/mBio.01750-18.

2.

The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation.

Mediouni S, Kessing CF, Jablonski JA, Thenin-Houssier S, Clementz M, Kovach MD, Mousseau G, de Vera IMS, Li C, Kojetin DJ, Evans DT, Valente ST.

FASEB J. 2019 Jul;33(7):8280-8293. doi: 10.1096/fj.201801165R. Epub 2019 Apr 25.

PMID:
31021670
3.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

PMID:
30918072
4.

Potent suppression of HIV-1 cell attachment by Kudzu root extract.

Mediouni S, Jablonski JA, Tsuda S, Richard A, Kessing C, Andrade MV, Biswas A, Even Y, Tellinghuisen T, Choe H, Cameron M, Stevenson M, Valente ST.

Retrovirology. 2018 Sep 20;15(1):64. doi: 10.1186/s12977-018-0446-x.

5.

In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.

Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, Garcia JV, Valente ST.

Cell Rep. 2017 Oct 17;21(3):600-611. doi: 10.1016/j.celrep.2017.09.080.

6.

Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection.

Takata H, Buranapraditkun S, Kessing C, Fletcher JL, Muir R, Tardif V, Cartwright P, Vandergeeten C, Bakeman W, Nichols CN, Pinyakorn S, Hansasuta P, Kroon E, Chalermchai T, O'Connell R, Kim J, Phanuphak N, Robb ML, Michael NL, Chomont N, Haddad EK, Ananworanich J, Trautmann L; RV254/SEARCH010 and the RV304/SEARCH013 Study Groups.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaag1809. doi: 10.1126/scitranslmed.aag1809.

7.

High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection.

Kessing CF, Spudich S, Valcour V, Cartwright P, Chalermchai T, Fletcher JL, Takata H, Nichols C, Josey BJ, Slike B, Krebs SJ, Sailsuta N, Lerdlum S, Jagodzinski L, Tipsuk S, Suttichom D, Rattanamanee S, Zetterberg H, Hellmuth J, Phanuphak N, Robb ML, Michael NL, Ananworanich J, Trautmann L.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):108-117. doi: 10.1097/QAI.0000000000001301.

8.

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Anderson AM, Lennox JL, Mulligan MM, Loring DW, Zetterberg H, Blennow K, Kessing C, Koneru R, Easley K, Tyor WR.

J Neurovirol. 2017 Feb;23(1):106-112. doi: 10.1007/s13365-016-0466-z. Epub 2016 Jul 11.

9.

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST.

MBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.

10.

Interferon-α induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor.

Kessing CF, Tyor WR.

J Interferon Cytokine Res. 2015 Apr;35(4):317-24. doi: 10.1089/jir.2014.0105. Epub 2014 Dec 17.

Supplemental Content

Loading ...
Support Center